Assessment of Phosphatidyl Serine-Specific Phospholipase A1, and CH50 in Sera of Systemic Lupus Erythematosus Patients and Its Correlation with Disease Activity, and Severity
(2023). Assessment of Phosphatidyl Serine-Specific Phospholipase A1, and CH50 in Sera of Systemic Lupus Erythematosus Patients and Its Correlation with Disease Activity, and Severity. EKB Journal Management System, 93(1), 6919-6927. doi: 10.21608/ejhm.2023.320229
. "Assessment of Phosphatidyl Serine-Specific Phospholipase A1, and CH50 in Sera of Systemic Lupus Erythematosus Patients and Its Correlation with Disease Activity, and Severity". EKB Journal Management System, 93, 1, 2023, 6919-6927. doi: 10.21608/ejhm.2023.320229
(2023). 'Assessment of Phosphatidyl Serine-Specific Phospholipase A1, and CH50 in Sera of Systemic Lupus Erythematosus Patients and Its Correlation with Disease Activity, and Severity', EKB Journal Management System, 93(1), pp. 6919-6927. doi: 10.21608/ejhm.2023.320229
Assessment of Phosphatidyl Serine-Specific Phospholipase A1, and CH50 in Sera of Systemic Lupus Erythematosus Patients and Its Correlation with Disease Activity, and Severity. EKB Journal Management System, 2023; 93(1): 6919-6927. doi: 10.21608/ejhm.2023.320229